Loading…
Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-κB pathway
Objective. To evaluate the effects of angiotensin II (Ang II) treatment on apoptosis of fibroblast-like synoviocytes (FLS) from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Methods. AT1 receptor expression was detected by western blotting and flow cytometry. Apoptosis induction w...
Saved in:
Published in: | Rheumatology (Oxford, England) England), 2007-08, Vol.46 (8), p.1252-1257 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 1257 |
container_issue | 8 |
container_start_page | 1252 |
container_title | Rheumatology (Oxford, England) |
container_volume | 46 |
creator | Pattacini, L. Casali, B. Boiardi, L. Pipitone, N. Albertazzi, L. Salvarani, C. |
description | Objective. To evaluate the effects of angiotensin II (Ang II) treatment on apoptosis of fibroblast-like synoviocytes (FLS) from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Methods. AT1 receptor expression was detected by western blotting and flow cytometry. Apoptosis induction was quantified by nucleosome ELISA and by TUNEL; cell proliferation was determined by a bromodeoxyuridine (BrdU) incorporation assay. Silencing of p65 NF-κB was obtained by using a specific siRNA. Caspase 3 activation was evaluated by a colorimetric assay and its cleavage by western blotting. Results. AT1 expression resulted comparable in FLS from OA and RA patients. Ang II pre-treatment reduced FLS apoptotic response to serum starvation and nitric oxide (NO) exposure. This protective effect was reverted in the presence of the AT1 receptor antagonist losartan as well as after silencing the expression of NF-κB. Moreover, FLS treatment with the caspase inhibitor z-VAD-fmk cancelled this Ang II effect on apoptosis. Caspase 3 activation was reduced in presence of Ang II. Conclusions. Ang II could represent an important mediator involved in FLS expansion, reducing their capacity to undergo apoptosis, through the activation of NF-κB and the blockage of caspase cascade. |
doi_str_mv | 10.1093/rheumatology/kem092 |
format | article |
fullrecord | <record><control><sourceid>proquest_pasca</sourceid><recordid>TN_cdi_proquest_miscellaneous_20299801</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/rheumatology/kem092</oup_id><sourcerecordid>20299801</sourcerecordid><originalsourceid>FETCH-LOGICAL-i293t-b7a36b45e566335776a1f6c412bdaa80e025c9f7bca32038e67cac6828e1291e3</originalsourceid><addsrcrecordid>eNpNkMtOwzAQRSMEEs8vYOMN7FL8SBx7WQqFIh4LQEIssCbGaU2TOMQukF_jI_gmgloBq5nRPXd0daNon-ABwZIdtTOzqCC40k27o7mpsKRr0RZJOI0xY3T9d6fJZrTt_QvGOCVMbEVPw3pqXTC1tzWaTFDT9ocOHhU2b11egg9xaecG-a52b9bpLphebF2FoHFNcN569GYBhZlBwzsSX4_jr89j1ECYvUO3G20UUHqzt5o70f349G50Hl_enE1Gw8vYUslCnGfAeJ6kJuWcsTTLOJCC64TQ_BlAYINpqmWR5RoYxUwYnmnQXFBhCJXEsJ3ocPm3z_-6MD6oynptyhJq4xZeUUylFJj04MEKBK-hLFqotfWqaW0FbaeIkIxhIXpusOTcovlTsfqpW_2vWy3r7g3x0mB9MB-_FmjnimcsS9X5w6O6vbpNkpPRhZLsG8vuiCY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20299801</pqid></control><display><type>article</type><title>Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-κB pathway</title><source>Oxford Journals Online</source><source>Alma/SFX Local Collection</source><creator>Pattacini, L. ; Casali, B. ; Boiardi, L. ; Pipitone, N. ; Albertazzi, L. ; Salvarani, C.</creator><creatorcontrib>Pattacini, L. ; Casali, B. ; Boiardi, L. ; Pipitone, N. ; Albertazzi, L. ; Salvarani, C.</creatorcontrib><description>Objective. To evaluate the effects of angiotensin II (Ang II) treatment on apoptosis of fibroblast-like synoviocytes (FLS) from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Methods. AT1 receptor expression was detected by western blotting and flow cytometry. Apoptosis induction was quantified by nucleosome ELISA and by TUNEL; cell proliferation was determined by a bromodeoxyuridine (BrdU) incorporation assay. Silencing of p65 NF-κB was obtained by using a specific siRNA. Caspase 3 activation was evaluated by a colorimetric assay and its cleavage by western blotting. Results. AT1 expression resulted comparable in FLS from OA and RA patients. Ang II pre-treatment reduced FLS apoptotic response to serum starvation and nitric oxide (NO) exposure. This protective effect was reverted in the presence of the AT1 receptor antagonist losartan as well as after silencing the expression of NF-κB. Moreover, FLS treatment with the caspase inhibitor z-VAD-fmk cancelled this Ang II effect on apoptosis. Caspase 3 activation was reduced in presence of Ang II. Conclusions. Ang II could represent an important mediator involved in FLS expansion, reducing their capacity to undergo apoptosis, through the activation of NF-κB and the blockage of caspase cascade.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/kem092</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Angiotensin II ; Apoptosis ; Biological and medical sciences ; Diseases of the osteoarticular system ; Fibroblast-like synoviocytes ; Inflammatory joint diseases ; Medical sciences ; Miscellaneous. Osteoarticular involvement in other diseases ; NF-κB ; Osteoarthritis ; Rheumatoid arthritis</subject><ispartof>Rheumatology (Oxford, England), 2007-08, Vol.46 (8), p.1252-1257</ispartof><rights>The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2007</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18933088$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Pattacini, L.</creatorcontrib><creatorcontrib>Casali, B.</creatorcontrib><creatorcontrib>Boiardi, L.</creatorcontrib><creatorcontrib>Pipitone, N.</creatorcontrib><creatorcontrib>Albertazzi, L.</creatorcontrib><creatorcontrib>Salvarani, C.</creatorcontrib><title>Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-κB pathway</title><title>Rheumatology (Oxford, England)</title><description>Objective. To evaluate the effects of angiotensin II (Ang II) treatment on apoptosis of fibroblast-like synoviocytes (FLS) from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Methods. AT1 receptor expression was detected by western blotting and flow cytometry. Apoptosis induction was quantified by nucleosome ELISA and by TUNEL; cell proliferation was determined by a bromodeoxyuridine (BrdU) incorporation assay. Silencing of p65 NF-κB was obtained by using a specific siRNA. Caspase 3 activation was evaluated by a colorimetric assay and its cleavage by western blotting. Results. AT1 expression resulted comparable in FLS from OA and RA patients. Ang II pre-treatment reduced FLS apoptotic response to serum starvation and nitric oxide (NO) exposure. This protective effect was reverted in the presence of the AT1 receptor antagonist losartan as well as after silencing the expression of NF-κB. Moreover, FLS treatment with the caspase inhibitor z-VAD-fmk cancelled this Ang II effect on apoptosis. Caspase 3 activation was reduced in presence of Ang II. Conclusions. Ang II could represent an important mediator involved in FLS expansion, reducing their capacity to undergo apoptosis, through the activation of NF-κB and the blockage of caspase cascade.</description><subject>Angiotensin II</subject><subject>Apoptosis</subject><subject>Biological and medical sciences</subject><subject>Diseases of the osteoarticular system</subject><subject>Fibroblast-like synoviocytes</subject><subject>Inflammatory joint diseases</subject><subject>Medical sciences</subject><subject>Miscellaneous. Osteoarticular involvement in other diseases</subject><subject>NF-κB</subject><subject>Osteoarthritis</subject><subject>Rheumatoid arthritis</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNpNkMtOwzAQRSMEEs8vYOMN7FL8SBx7WQqFIh4LQEIssCbGaU2TOMQukF_jI_gmgloBq5nRPXd0daNon-ABwZIdtTOzqCC40k27o7mpsKRr0RZJOI0xY3T9d6fJZrTt_QvGOCVMbEVPw3pqXTC1tzWaTFDT9ocOHhU2b11egg9xaecG-a52b9bpLphebF2FoHFNcN569GYBhZlBwzsSX4_jr89j1ECYvUO3G20UUHqzt5o70f349G50Hl_enE1Gw8vYUslCnGfAeJ6kJuWcsTTLOJCC64TQ_BlAYINpqmWR5RoYxUwYnmnQXFBhCJXEsJ3ocPm3z_-6MD6oynptyhJq4xZeUUylFJj04MEKBK-hLFqotfWqaW0FbaeIkIxhIXpusOTcovlTsfqpW_2vWy3r7g3x0mB9MB-_FmjnimcsS9X5w6O6vbpNkpPRhZLsG8vuiCY</recordid><startdate>20070801</startdate><enddate>20070801</enddate><creator>Pattacini, L.</creator><creator>Casali, B.</creator><creator>Boiardi, L.</creator><creator>Pipitone, N.</creator><creator>Albertazzi, L.</creator><creator>Salvarani, C.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>7QP</scope></search><sort><creationdate>20070801</creationdate><title>Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-κB pathway</title><author>Pattacini, L. ; Casali, B. ; Boiardi, L. ; Pipitone, N. ; Albertazzi, L. ; Salvarani, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i293t-b7a36b45e566335776a1f6c412bdaa80e025c9f7bca32038e67cac6828e1291e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Angiotensin II</topic><topic>Apoptosis</topic><topic>Biological and medical sciences</topic><topic>Diseases of the osteoarticular system</topic><topic>Fibroblast-like synoviocytes</topic><topic>Inflammatory joint diseases</topic><topic>Medical sciences</topic><topic>Miscellaneous. Osteoarticular involvement in other diseases</topic><topic>NF-κB</topic><topic>Osteoarthritis</topic><topic>Rheumatoid arthritis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pattacini, L.</creatorcontrib><creatorcontrib>Casali, B.</creatorcontrib><creatorcontrib>Boiardi, L.</creatorcontrib><creatorcontrib>Pipitone, N.</creatorcontrib><creatorcontrib>Albertazzi, L.</creatorcontrib><creatorcontrib>Salvarani, C.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Calcium & Calcified Tissue Abstracts</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pattacini, L.</au><au>Casali, B.</au><au>Boiardi, L.</au><au>Pipitone, N.</au><au>Albertazzi, L.</au><au>Salvarani, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-κB pathway</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><date>2007-08-01</date><risdate>2007</risdate><volume>46</volume><issue>8</issue><spage>1252</spage><epage>1257</epage><pages>1252-1257</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>Objective. To evaluate the effects of angiotensin II (Ang II) treatment on apoptosis of fibroblast-like synoviocytes (FLS) from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Methods. AT1 receptor expression was detected by western blotting and flow cytometry. Apoptosis induction was quantified by nucleosome ELISA and by TUNEL; cell proliferation was determined by a bromodeoxyuridine (BrdU) incorporation assay. Silencing of p65 NF-κB was obtained by using a specific siRNA. Caspase 3 activation was evaluated by a colorimetric assay and its cleavage by western blotting. Results. AT1 expression resulted comparable in FLS from OA and RA patients. Ang II pre-treatment reduced FLS apoptotic response to serum starvation and nitric oxide (NO) exposure. This protective effect was reverted in the presence of the AT1 receptor antagonist losartan as well as after silencing the expression of NF-κB. Moreover, FLS treatment with the caspase inhibitor z-VAD-fmk cancelled this Ang II effect on apoptosis. Caspase 3 activation was reduced in presence of Ang II. Conclusions. Ang II could represent an important mediator involved in FLS expansion, reducing their capacity to undergo apoptosis, through the activation of NF-κB and the blockage of caspase cascade.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><doi>10.1093/rheumatology/kem092</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1462-0324 |
ispartof | Rheumatology (Oxford, England), 2007-08, Vol.46 (8), p.1252-1257 |
issn | 1462-0324 1462-0332 |
language | eng |
recordid | cdi_proquest_miscellaneous_20299801 |
source | Oxford Journals Online; Alma/SFX Local Collection |
subjects | Angiotensin II Apoptosis Biological and medical sciences Diseases of the osteoarticular system Fibroblast-like synoviocytes Inflammatory joint diseases Medical sciences Miscellaneous. Osteoarticular involvement in other diseases NF-κB Osteoarthritis Rheumatoid arthritis |
title | Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-κB pathway |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T11%3A36%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Angiotensin%20II%20protects%20fibroblast-like%20synoviocytes%20from%20apoptosis%20via%20the%20AT1-NF-%CE%BAB%20pathway&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Pattacini,%20L.&rft.date=2007-08-01&rft.volume=46&rft.issue=8&rft.spage=1252&rft.epage=1257&rft.pages=1252-1257&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/kem092&rft_dat=%3Cproquest_pasca%3E20299801%3C/proquest_pasca%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-i293t-b7a36b45e566335776a1f6c412bdaa80e025c9f7bca32038e67cac6828e1291e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20299801&rft_id=info:pmid/&rft_oup_id=10.1093/rheumatology/kem092&rfr_iscdi=true |